BioCentury | Sep 7, 2018
Clinical News

Fosun to start clinical testing in China for Yescarta

...China's National Medical Products Administration (NMPA) approved an application from Fosun Pharma Kite Biotechnology Co. Ltd. to...
...large B cell lymphoma. Fosun Kite Pharma plans to begin Phase I testing "when ready." Fosun Pharma...
BioCentury | Mar 23, 2018
Company News

Fosun Pharma gets rights to Dova's avatrombopag

The AkaRx Inc. subsidiary of Dova Pharmaceuticals Inc. (NASDAQ:DOVA) granted the Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. subsidiary of Shanghai Fosun Pharmaceutical Group Co. Ltd. (Shanghai:600196; HKSE:2196) exclusive development and commercialization rights in mainland...
BioCentury | Jun 23, 2017
Clinical News

Kite reports additional Phase I ZUMA-3 data of axicabtagene ciloleucel in ALL

...Sankyo Co. Ltd. (Tokyo:4568) has Japanese rights to develop and commercialize axicabtagene ciloleucel from Kite. Fosun Pharma...
BioCentury | May 11, 2017
Clinical News

Kite reports patient death in expansion cohort of ZUMA-1 trial

...Sankyo Co. Ltd. (Tokyo:4568) has Japanese rights to develop and commercialize axicabtagene ciloleucel from Kite. Fosun Pharma...
BioCentury | Apr 12, 2017
Clinical News

Axicabtagene ciloleucel: Updated Ph I/II ZUMA-1 data

...has Japanese rights to develop and commercialize axicabtagene ciloleucel from Kite. Kite and Fosun's JV Fosun Pharma...
BioCentury | Mar 10, 2017
Clinical News

Axicabtagene ciloleucel: Additional Ph I/II ZUMA-1 data

...has Japanese rights to develop and commercialize axicabtagene ciloleucel from Kite. Kite and Fosun's JV Fosun Pharma...
BioCentury | Jan 13, 2017
Company News

Kite, Fosun deal

...Kite and Fosun formed the JV Fosun Pharma Kite Biotechnology Co. Ltd. (Shanghai, China) to develop Kite's...
BioCentury | Feb 15, 2016
Financial News

Phagelux completes venture financing

...China Business: Infectious, Veterinary, Agbio/Environmental Date completed: 2016-02-05 Type: Venture financing Raised: Not disclosed Investor: Fosun Pharma...
BioCentury | Oct 27, 2014
Financial News

Check-Cap completes venture financing

...Isfiya, Israel Business: Diagnostic Date completed: 2014-10-19 Type: Venture financing Raised: Not disclosed Investors: Fosun Pharma...
BioCentury | Oct 25, 2012
Top Story

Fosun Pharma raises $511.6M in Hong Kong

Shanghai Fosun Pharmaceuticals Group Co. Ltd. (Shanghai:600196) raised HK$4 billion ($511.6 million) through the sale of 336.1 million shares at HK$11.80 in a listing on the Hong Kong Stock Exchange, according to a source familiar...
Items per page:
1 - 10 of 12
BioCentury | Sep 7, 2018
Clinical News

Fosun to start clinical testing in China for Yescarta

...China's National Medical Products Administration (NMPA) approved an application from Fosun Pharma Kite Biotechnology Co. Ltd. to...
...large B cell lymphoma. Fosun Kite Pharma plans to begin Phase I testing "when ready." Fosun Pharma...
BioCentury | Mar 23, 2018
Company News

Fosun Pharma gets rights to Dova's avatrombopag

The AkaRx Inc. subsidiary of Dova Pharmaceuticals Inc. (NASDAQ:DOVA) granted the Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. subsidiary of Shanghai Fosun Pharmaceutical Group Co. Ltd. (Shanghai:600196; HKSE:2196) exclusive development and commercialization rights in mainland...
BioCentury | Jun 23, 2017
Clinical News

Kite reports additional Phase I ZUMA-3 data of axicabtagene ciloleucel in ALL

...Sankyo Co. Ltd. (Tokyo:4568) has Japanese rights to develop and commercialize axicabtagene ciloleucel from Kite. Fosun Pharma...
BioCentury | May 11, 2017
Clinical News

Kite reports patient death in expansion cohort of ZUMA-1 trial

...Sankyo Co. Ltd. (Tokyo:4568) has Japanese rights to develop and commercialize axicabtagene ciloleucel from Kite. Fosun Pharma...
BioCentury | Apr 12, 2017
Clinical News

Axicabtagene ciloleucel: Updated Ph I/II ZUMA-1 data

...has Japanese rights to develop and commercialize axicabtagene ciloleucel from Kite. Kite and Fosun's JV Fosun Pharma...
BioCentury | Mar 10, 2017
Clinical News

Axicabtagene ciloleucel: Additional Ph I/II ZUMA-1 data

...has Japanese rights to develop and commercialize axicabtagene ciloleucel from Kite. Kite and Fosun's JV Fosun Pharma...
BioCentury | Jan 13, 2017
Company News

Kite, Fosun deal

...Kite and Fosun formed the JV Fosun Pharma Kite Biotechnology Co. Ltd. (Shanghai, China) to develop Kite's...
BioCentury | Feb 15, 2016
Financial News

Phagelux completes venture financing

...China Business: Infectious, Veterinary, Agbio/Environmental Date completed: 2016-02-05 Type: Venture financing Raised: Not disclosed Investor: Fosun Pharma...
BioCentury | Oct 27, 2014
Financial News

Check-Cap completes venture financing

...Isfiya, Israel Business: Diagnostic Date completed: 2014-10-19 Type: Venture financing Raised: Not disclosed Investors: Fosun Pharma...
BioCentury | Oct 25, 2012
Top Story

Fosun Pharma raises $511.6M in Hong Kong

Shanghai Fosun Pharmaceuticals Group Co. Ltd. (Shanghai:600196) raised HK$4 billion ($511.6 million) through the sale of 336.1 million shares at HK$11.80 in a listing on the Hong Kong Stock Exchange, according to a source familiar...
Items per page:
1 - 10 of 12